RIGL News & Events

Rigel Pharmaceuticals sees FY26 revenue $275M-$290M, consensus $279.31M

Reports Q4 revenue $69.8M, consensus $68.7M. Q4 EPS includes a benefit from income taxes of $245.4M, primarily driven by $245.9M of non-cash deferred income tax benefit, partially offset by state tax expenses. "I am proud to highlight Rigel's tremendous progress during 2025 across each of the key value drivers of our business. We delivered record net product sales, total revenues and net income while making meaningful advances in our Phase 1b study of R289 in lower-risk MDS," said Raul Rodriguez, Rigel's president and CEO. "These 2025 accomplishments set the stage for a strong 2026, as reflected in our financial guidance and our plans to advance our R289 program in lower-risk MDS and other potential indications."

Rigel anticipates full-year total revenue of approximately $275M-$290M, including net product sales of $255M-$265M, and positive net income for the full year. "2025 was an excellent year for Rigel, marked by strong commercial execution with record net product sales; significant financial progress, including continued profitability and generation of $77 million in cash; and meaningful clinical advancement of R289 in lower-risk MDS, where we shared encouraging Phase 1b data," said Raul Rodriguez, Rigel's president and CEO. "In 2026, we plan to continue to execute across all areas of the business - driving sustained commercial performance, supporting our expanding clinical programs with a solid financial foundation, delivering preliminary results from the dose expansion phase of our R289 study and continuing to explore opportunities to add new products to our portfolio."